Literature DB >> 2302720

Successful chemotherapy of experimental neuroendocrine lung tumors in hamsters with an antagonist of Ca2+/calmodulin.

H M Schuller1, E Correa, M Orloff, G K Reznik.   

Abstract

The chemotherapeutic effect of B859-35, the (-)-enantiomer of dihydropyrine 3-methyl-5-3-(4,4-diphenyl-1-piperidinyl)-propyl-1,4-dihydro-2,6-dimethy l-4- (3-nitrophenyl)-pyridine-3,5-dicarboxylate-hydrochloride (niguldipine), was tested on tumors induced in Syrian golden hamsters by N-nitrosodiethylamine (DEN). Peripheral pulmonary adenomas/adenocarcinomas were induced in hamsters maintained under ambient air conditions by multiple s.c. injections of DEN for 20 weeks. We have reproducibly shown that within this time interval lung adenomas develop in a significant number of the animals. The carcinogen treatment was discontinued at this point and one group of these hamsters was given B859-35 intragastrically 5 days/week for 20 weeks while the second group of such tumor-bearing hamsters were kept for an identical time interval without further treatment. Neuroendocrine lung tumors were induced in hamsters maintained in an atmosphere of 60% O2 by multiple s.c. injections of DEN for 8 weeks. We have reproducibly shown that within this short time interval neuroendocrine lung tumors develop in a significant number of the animals. The carcinogen treatment was discontinued at this point and the animals were returned to ambient air conditions. One group of these tumor-bearing hamsters was then given B859-35 intragastrically 5 days/week for 20 weeks while a second group of these hamsters was kept untreated for an identical time interval. A control group was given s.c. injections of saline for 20 weeks under ambient air conditions. A dramatic and selective anticarcinogenic effect of B859-35 was observed on the neuroendocrine lung tumors and nasal cavity tumors induced by DEN/hyperoxia while tumors of larynx/trachea were not affected. B859-35 had no effect on peripheral adenomas/adenocarcinomas, nasal cavity tumors, papillary polyps of larynx/trachea, or liver tumors induced by DEN under ambient air conditions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2302720

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine.

Authors:  J Hofmann; A Wolf; M Spitaler; G Böck; J Drach; C Ludescher; H Grunicke
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model.

Authors:  W Van de Vrie; J H Schellens; W J Loss; H J Kolker; J Verwey; G Stoter; N M Durante; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1.

Authors:  Yong P Hwang; Hye G Jeong
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  A novel Ca2+/calmodulin antagonist HBC inhibits angiogenesis and down-regulates hypoxia-inducible factor.

Authors:  Hye Jin Jung; Jong Hyeon Kim; Joong Sup Shim; Ho Jeong Kwon
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

5.  Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCl.

Authors:  A Reymann; G Looft; C Woermann; M Dietel; R Erttmann
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Nitrosamines as nicotinic receptor ligands.

Authors:  Hildegard M Schuller
Journal:  Life Sci       Date:  2007-03-19       Impact factor: 5.037

7.  Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial.

Authors:  D Ukena; C Boewer; B Oldenkott; F Rathgeb; W Wurst; K Zech; G W Sybrecht
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Histochemical characterization of non-neuroendocrine tumors and neuroendocrine cell hyperplasia induced in hamster lung by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone with or without hyperoxia.

Authors:  M E Sunday; C G Willett; S A Graham; V I Oreffo; R I Linnoila; H Witschi
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

9.  Inhibition of protein-kinase-C--dependent cell proliferation of human lung cancer cell lines by the dihydropyridine dexniguldipine.

Authors:  H M Schuller; M Orloff; G K Reznik
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Identification of CALM as the potential serum biomarker for predicting the recurrence of nasopharyngeal carcinoma using a mass spectrometry-based comparative proteomic approach.

Authors:  Huiling Meng; Xiaodong Zhu; Ling Li; Zhongguo Liang; Xiaoyu Li; Xinbin Pan; Fanyan Zeng; Song Qu
Journal:  Int J Mol Med       Date:  2017-08-09       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.